Our mission is to improve the quality of human cell culture and research everywhere and become the go-to manufacturer of iPSC-derived cells for all applications. With Life Sciences and Pharmaceutical research still relying on research methods from the 20th century, the stage is set for next-generation human cell models.
Celogics’ aim is to make quality human cells that are not just great iPSC-derived cells but the best functional cells for the research subject. We will listen to our users’ needs and provide the high-quality cells they deserve. Our initial product offering will be research-use-only iPSC-derived cell products, under our Celo.Cells brand. These cell products are used in drug discovery, drug safety screening, and disease modeling.
We are a newly formed joint venture between Curi Bio (www.curibio.com) & NEXEL (www.nexel.co.kr) and building out a 22,000 square feet facility – reach out and join our exciting project!
Company Details
- Employees
- 5
- Founded
- -
- Address
- 222 Fifth Ave N, Seattle,washington 98109,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.celogics.com
- Keywords
- for pharmaceutical research.
- HQ
- Seattle, Washington
Celogics Questions
Celogics's website is http://www.celogics.com
Celogics's LinkedIn profile is https://www.linkedin.com/company/celogics-seattle
Celogics has
5 employees.
View email and phone details for 5
employees at Celogics.
Celogics's industry is
Biotechnology Research
Celogics's top competitors are
Soundeats,
Teatro Zinzanni,
S2m Solutions,
Convergent Manufacturing Technologies Us Inc.,
Curi Bio,
C & C Biotech Llc,
Kinea Bio,
Decycle Bio,
Foresee Biosystems,
Hox.
Celogics's categories are Biotechnology Research
Celogics's founding year is 2021
